Article
JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $21
JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $21.
Comments
- No comments yet. Be the first to comment!